Genmab — Februar 2015
-
Nej men vores opgave som investorer nu er jo at vurdere om data er stærke nok til at de kan søge om godkendelse - og det er jeg ret sikker på det er !! I første omgang er det jo blot godkendelse i RRMM, altså for patienter der ikke har ret mange behandlingstilbud tilbage.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind